{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":464,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":464,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"e82fe8a4975b","filters":{"venue":"Leukemia"}},"results":[{"id":"W4283271244","doi":"10.1038/s41375-022-01613-1","title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms","year":2022,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3904,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hospital for Sick Children","funders":"Sahlgrenska Akademin; National Cancer Institute; Department of Laboratory Medicine and Pathology, University of Washington; School of Medicine, Indiana University; University of Texas MD Anderson Cancer Center; Universitätsklinikum Jena; Hospital for Sick Children; University of California, San Diego; National University Cancer Institute, Singapore; Medizinischen Hochschule Hannover; Université de Montréal; Centre National de la Recherche Scientifique; School of Medicine, Stanford University; Fudan University; Institut Gustave-Roussy; Sahlgrenska Universitetssjukhuset; Vrije Universiteit Amsterdam; University of Oxford; Wellcome Trust; University of Southampton; University of Alabama; Texas Children's Hospital; Amsterdam University Medical Centers; Moffitt Cancer Center; Institut National de la Santé et de la Recherche Médicale; University of Washington; Memorial Sloan-Kettering Cancer Center; Knight Cancer Institute, Oregon Health and Science University; Universität Ulm; University of Texas Southwestern Medical Center; Imperial College London; Children's Hospital Los Angeles; National Institute for Health and Care Research; Assistance publique-Hôpitaux de Paris; Massachusetts General Hospital; Université Paris-Saclay; University of Alabama at Birmingham; Nationwide Children's Hospital; Cincinnati Children's Hospital Medical Center; Centre International de Recherche sur le Cancer; Göteborgs Universitet; Radboud Universiteit; Radboud Universitair Medisch Centrum; Università degli Studi di Milano; University of Pennsylvania","keywords":"Histiocyte; Myeloid; Disease; Hematologic Neoplasms; Medicine; Computational biology; Computer science; Biology; Pathology; Immunology; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04478243319244866,"gpt":0.3376422626290177,"spread":0.292859829436569,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001045786,0.0003584656,0.001453509,0.0003341848,0.0004787921,0.00003601375,0.0005455898,0.0001946007,0.0001700445],"category_scores_gemma":[0.001246551,0.0002208232,0.0002507881,0.00205353,0.0004759075,0.00007693309,0.0003159161,0.0009819603,0.0000135445],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.006722751,"about_ca_system_score_gemma":0.009647319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002367015,"about_ca_topic_score_gemma":0.0001117981,"domain_scores_codex":[0.9962679,0.0006537988,0.001237121,0.0004673174,0.0009733722,0.0004005513],"domain_scores_gemma":[0.995967,0.001234087,0.001335884,0.00104266,0.0002650968,0.0001552931],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007921431,0.0001330539,0.0003989306,0.04888215,0.0003601416,0.00001944406,0.0005562495,0.000005497936,0.00008669014,0.01055409,0.04955652,0.889368],"study_design_scores_gemma":[0.0008764591,0.0001519261,0.001116762,0.007322699,0.00073908,0.000668202,0.0002152588,0.0002153572,0.0001332644,0.0000890302,0.9882489,0.0002230242],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004876476,0.9936566,0.0000887586,0.001603309,0.000643023,0.002446415,0.0001317186,0.00005753667,0.000884958],"genre_scores_gemma":[0.00221637,0.9935517,0.0001284967,0.0001489261,0.0002853589,0.0001534119,0.0005584247,0.0001137136,0.002843597],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9386924,"threshold_uncertainty_score":0.9970903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.04811984751068918,"gpt":0.3335786658783663,"spread":0.2854588183676771,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0006163816,0.002006306,0.005048637,0.0004206924,0.0005140917,0.0001921342,0.0009845461,0.0009501692,0.0009842302],"category_scores_gemma":[0.00064773,0.001792925,0.002362353,0.001213002,0.0001980659,0.00023839,0.000462452,0.002183887,0.00317014],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.06540783,"about_ca_system_score_gemma":0.02233397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000173426,"about_ca_topic_score_gemma":0.00004545317,"domain_scores_codex":[0.9923265,0.0005416499,0.002532126,0.002343633,0.0006770897,0.001579008],"domain_scores_gemma":[0.9943925,0.0009825489,0.001452723,0.001935206,0.0001949013,0.001042112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005507133,0.00004443162,0.000002638267,0.02005261,0.001289832,0.0005461125,0.000144761,0.000008845145,0.00001238638,0.00008992318,0.1092763,0.868477],"study_design_scores_gemma":[0.005591969,0.0007023793,0.000005935927,0.021949,0.006536294,0.001323955,0.00004505554,0.000423934,0.00002357746,0.00002112533,0.9620646,0.001312216],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001489467,0.9722241,0.0003072627,0.0006631429,0.0008841562,0.005604379,0.0009621062,0.0008580058,0.01848196],"genre_scores_gemma":[0.00002543741,0.9618719,0.006488719,0.0006299658,0.005634998,0.001220149,0.01174417,0.0008703353,0.01151431],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8671649,"threshold_uncertainty_score":0.999929,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086275775","doi":"10.1038/sj.leu.2404296","title":"Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication","year":2006,"lang":"en","type":"review","venue":"Leukemia","topic":"Extracellular vesicles in disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1336,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Microvesicles; Cell biology; Biology; Cell; Secretion; Endosome; Cell signaling; Immune system; Organelle; Receptor; Mitochondrion; Signal transduction; Immunology; microRNA; Biochemistry; Intracellular","retraction":null,"screen_n_in":null,"score":{"opus":0.01055598367897123,"gpt":0.2623132149103545,"spread":0.2517572312313833,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002336441,0.000427173,0.000816456,0.0001070389,0.00006360924,0.00002661373,0.0005739956,0.000543638,0.00001117243],"category_scores_gemma":[0.00004501932,0.0004144205,0.000296514,0.0001888435,0.0001521914,0.000003637303,0.0003248884,0.0002352618,0.00001166552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001087206,"about_ca_system_score_gemma":0.000589828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005388948,"about_ca_topic_score_gemma":0.00002207084,"domain_scores_codex":[0.9979513,0.0002290249,0.0008282625,0.0005444475,0.0001651196,0.0002817988],"domain_scores_gemma":[0.9979556,0.0000616859,0.000630206,0.001104528,0.00006889772,0.0001790741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007411701,0.0003341312,0.00007383504,0.02133079,0.0003068879,0.00002660497,0.0001273298,0.00002374784,0.8736419,0.00003727694,0.008844462,0.09517889],"study_design_scores_gemma":[0.0007856204,0.000106516,0.00001924096,0.001294883,0.0006642285,0.00001497301,0.00003903087,0.00001030418,0.2565433,0.00003589272,0.7397509,0.0007351317],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03961133,0.9586931,0.00006244369,0.000005066797,0.00006102507,0.0006544979,0.0001432128,0.00001923531,0.0007500317],"genre_scores_gemma":[0.0100605,0.9860695,0.001502077,0.00005901002,0.00008483163,0.00005325223,0.001636436,0.0001047782,0.0004296321],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7309064,"threshold_uncertainty_score":0.9998308,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015880063","doi":"10.1038/leu.2009.174","title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","year":2009,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":878,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Saint John Regional Hospital; Dalhousie University","funders":"National Cancer Institute; National Institute on Aging","keywords":"Multiple myeloma; Chromosomal translocation; Biology; Cancer research; Hematology; Cytogenetics; Comparative genomic hybridization; Gene expression profiling; Gene; Oncology; Genetics; Chromosome; Immunology; Gene expression; Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0645365481067835,"gpt":0.3601065434952254,"spread":0.2955699953884419,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003930887,0.0005798784,0.002271626,0.0004249214,0.0000595679,0.00002991821,0.0005230834,0.0004115688,0.000230697],"category_scores_gemma":[0.0005226615,0.0004507757,0.0009739947,0.0006323135,0.00009168199,0.00008162195,0.0001220121,0.0006802281,0.0002605332],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001550754,"about_ca_system_score_gemma":0.0006640792,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000021158,"about_ca_topic_score_gemma":0.000003915982,"domain_scores_codex":[0.9963749,0.0002195273,0.001210513,0.0007323002,0.0009852722,0.0004774987],"domain_scores_gemma":[0.9975725,0.0002178918,0.000742404,0.0009641485,0.000206456,0.0002966129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004591035,0.0001492625,0.0001221467,0.02399782,0.0005921386,0.0004746209,0.000007296412,1.023914e-7,0.000058018,0.0002207947,0.001299154,0.9730327],"study_design_scores_gemma":[0.001134454,0.00011949,0.00124161,0.09451959,0.001177029,0.0002743683,0.000002392767,0.00006059337,0.00002547595,0.0000138846,0.9011445,0.0002866048],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004198384,0.9849616,0.0001191466,0.0001618374,0.0002130526,0.002178949,0.00004678159,0.00009041216,0.01218621],"genre_scores_gemma":[0.001073368,0.9928744,0.00218033,0.0001728315,0.0003069321,0.0002675434,0.002344101,0.00009326918,0.0006872409],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9727461,"threshold_uncertainty_score":0.9997944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137749199","doi":"10.1038/sj.leu.2402238","title":"Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc − cystine transporter: a new action for an old drug","year":2001,"lang":"en","type":"article","venue":"Leukemia","topic":"Amino Acid Enzymes and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":638,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; BC Cancer Agency; Ohio Cancer Research Associates","keywords":"Sulfasalazine; Cystine; Growth inhibition; Lymphoma; Pharmacology; Chemistry; Cancer research; Biology; Medicine; Biochemistry; In vitro; Immunology; Internal medicine; Cysteine","retraction":null,"screen_n_in":null,"score":{"opus":0.01024197766002419,"gpt":0.2313642108299646,"spread":0.2211222331699404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008205276,0.0001208273,0.0001586792,0.0000205971,0.00002956353,0.00000475312,0.0001247435,0.0001130134,0.000006338352],"category_scores_gemma":[0.00001848661,0.00009307304,0.0001375451,0.00007801186,0.00004955372,0.000008712785,0.00001986548,0.00003409975,3.457198e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002926861,"about_ca_system_score_gemma":0.0001416185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005373147,"about_ca_topic_score_gemma":0.0001195741,"domain_scores_codex":[0.9992586,0.00002470729,0.0002388371,0.0002064877,0.0001108088,0.0001605385],"domain_scores_gemma":[0.9994409,0.000005318628,0.0001470307,0.0002644956,0.0000794119,0.00006283113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000227648,0.0000635652,0.0005049834,0.00003967974,0.00002320498,3.418282e-7,0.0001079921,0.00003142642,0.9811081,0.00009579737,0.01298111,0.004816105],"study_design_scores_gemma":[0.001888626,0.0001493222,0.009422562,0.00001966226,0.00005810306,0.00001258504,0.00005140061,0.00009343276,0.9601874,0.0001077568,0.0279005,0.0001086861],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954077,0.0003989767,0.003242419,0.0001643182,0.0001619191,0.0002545935,0.0001058295,0.000007893682,0.0002563584],"genre_scores_gemma":[0.9947314,0.0002234191,0.000348076,0.0001801272,0.0002125816,0.0000181442,0.0002864225,0.00002006991,0.003979797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02092078,"threshold_uncertainty_score":0.3795408,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079430799","doi":"10.1038/sj.leu.2402476","title":"HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis","year":2002,"lang":"en","type":"review","venue":"Leukemia","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":577,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mevalonate pathway; Farnesyl pyrophosphate; Statin; Geranylgeranyl pyrophosphate; Cancer research; Apoptosis; HMG-CoA reductase; In vivo; Pharmacology; Medicine; Cancer; Reductase; Biology; Internal medicine; Enzyme; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01444525543920106,"gpt":0.2513972591500457,"spread":0.2369520037108447,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005262033,0.0004148023,0.001194929,0.00007384434,0.00008907462,0.00002514279,0.0004726271,0.0002514125,0.00002365103],"category_scores_gemma":[0.0000544692,0.0002295978,0.0005905018,0.0002323456,0.0006691442,0.000003276086,0.0001655756,0.0002905292,0.000007015479],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006070029,"about_ca_system_score_gemma":0.0005394638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003042367,"about_ca_topic_score_gemma":0.000002982382,"domain_scores_codex":[0.9977661,0.000338181,0.0008288855,0.0004879308,0.0002805116,0.0002983288],"domain_scores_gemma":[0.9981272,0.000113737,0.0007579657,0.0008304166,0.00008792473,0.00008272592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002314305,0.00007521464,0.000001042589,0.005771295,0.0003759723,5.294049e-7,0.001004769,0.000008961701,0.01494103,0.0005388504,0.1968982,0.7801527],"study_design_scores_gemma":[0.00100821,0.00006895834,9.818841e-7,0.000785342,0.0004432924,0.00001097827,0.0004549089,0.000001327313,0.01142525,0.00002503207,0.9855211,0.0002546048],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.005486366,0.9894266,0.000006792636,0.00002902026,0.0020728,0.0007782878,0.0002202681,0.000005907512,0.001973954],"genre_scores_gemma":[0.001033233,0.9946059,0.00007480373,0.0001048784,0.002821013,0.0001047549,0.0001044573,0.00005712874,0.001093833],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.788623,"threshold_uncertainty_score":0.9362727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2030873172","doi":"10.1038/sj.leu.2402114","title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","year":2001,"lang":"en","type":"review","venue":"Leukemia","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":492,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Ligue Contre le Cancer; Alberta Cancer Foundation; Friedreich's Ataxia Research Alliance","keywords":"Nucleoside transporter; Nucleoside analogue; Cladribine; Nucleoside; Fludarabine; Pharmacology; Intracellular; Transporter; Drug resistance; Gemcitabine; ATP-binding cassette transporter; Deoxycytidine kinase; Mechanism of action; Drug; Biology; Cancer research; Biochemistry; In vitro; Chemotherapy; Deoxycytidine; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01701804877374928,"gpt":0.2768646023809644,"spread":0.2598465536072151,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001383037,0.0002850483,0.0006826485,0.00005823994,0.00004413239,0.0000248144,0.0002262904,0.0003011491,0.00002037127],"category_scores_gemma":[0.00002523086,0.0002477253,0.0001947383,0.0001340376,0.00007705727,0.0000041555,0.0001075013,0.0001657196,0.000004230038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003700673,"about_ca_system_score_gemma":0.0004069225,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004800784,"about_ca_topic_score_gemma":0.00002771071,"domain_scores_codex":[0.9988398,0.00007732303,0.0003801607,0.0003911282,0.0001127285,0.0001988363],"domain_scores_gemma":[0.9992409,0.00002696233,0.0002746666,0.000353546,0.00004348618,0.00006043523],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002692335,0.0001839472,0.00002855385,0.09403889,0.003091842,0.0005867819,0.0005379414,0.0001085414,0.009775454,0.03724694,0.5097771,0.3443548],"study_design_scores_gemma":[0.0001560177,0.00003659061,0.000001108851,0.00224926,0.0002598738,0.00003636666,0.0000871944,9.172454e-7,0.0004058673,0.0008632258,0.9956149,0.0002887207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001462233,0.995676,0.001295043,0.000007872197,0.00007144993,0.0001599414,0.00003592931,0.00001059725,0.002596971],"genre_scores_gemma":[0.0005608881,0.9937378,0.00115576,0.00003777247,0.0002202356,0.00001387008,0.0002616542,0.0000411771,0.00397088],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4858378,"threshold_uncertainty_score":0.9999975,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905344869","doi":"10.1038/s41375-018-0312-9","title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":489,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Charles-Le Moyne","funders":"European Hematology Association; Pfizer","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Myeloid leukemia; Oncology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.008878858709095296,"gpt":0.2468187925637455,"spread":0.2379399338546502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003707664,0.0005737564,0.001505582,0.0001666293,0.0001487521,0.00003347895,0.0004140991,0.0002880803,0.00004000633],"category_scores_gemma":[0.0004760232,0.0003437437,0.0001089609,0.0004728197,0.0008657203,0.00001795832,0.0001782788,0.0003119331,0.00002561567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002934675,"about_ca_system_score_gemma":0.0009466601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005397361,"about_ca_topic_score_gemma":0.00229722,"domain_scores_codex":[0.997088,0.0002861179,0.0007324175,0.0007971582,0.0004735099,0.000622862],"domain_scores_gemma":[0.9979122,0.0002673907,0.0005876924,0.0006959009,0.0003654068,0.0001714647],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6038018,0.0005797527,0.3692804,0.0002978222,0.002312328,0.000225154,0.001649463,0.00372851,0.01544086,0.00001428981,0.0009780434,0.001691594],"study_design_scores_gemma":[0.6801578,0.0180602,0.2123533,0.001196284,0.001160369,0.00006119907,0.0003595242,0.002793081,0.08148793,0.00001993459,0.0005752249,0.001775107],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964133,0.00008726975,0.001820112,0.00002025409,0.0001801665,0.001271734,0.00008777026,0.00004483692,0.00007455473],"genre_scores_gemma":[0.9950094,0.00008167533,0.003683682,0.00009823022,0.0001450715,0.0001749201,0.0001843423,0.00009614209,0.0005265036],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1569271,"threshold_uncertainty_score":0.9999015,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1976615153","doi":"10.1038/sj.leu.2404624","title":"A tumor suppressor and oncogene: the WT1 story","year":2007,"lang":"en","type":"review","venue":"Leukemia","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":476,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Wilms' tumor; Biology; Cancer research; Suppressor; Oncogene; Tumor suppressor gene; Transcription factor; Gene; Cancer; Leukemia; Carcinogenesis; Genetics; Cell cycle","retraction":null,"screen_n_in":null,"score":{"opus":0.01990857351068483,"gpt":0.2988031246577936,"spread":0.2788945511471088,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002099329,0.0002832371,0.0004432223,0.00003520544,0.0001069545,0.00002169121,0.0002771148,0.0004156737,0.00001209771],"category_scores_gemma":[0.00002779306,0.000153388,0.0002633684,0.0000815249,0.0001577042,0.000001032697,0.0001275061,0.000458301,0.00002671379],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001205544,"about_ca_system_score_gemma":0.0005370346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001850434,"about_ca_topic_score_gemma":0.000009229857,"domain_scores_codex":[0.9989674,0.00009559231,0.0002131757,0.0003632038,0.0001115524,0.0002490652],"domain_scores_gemma":[0.9993336,0.00003329981,0.0001457217,0.0003799604,0.00002338612,0.0000840206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001413739,0.000005102322,5.61508e-7,0.001867957,0.0002593336,0.00003289121,0.00001588879,0.000003035079,0.0003176696,0.00002114172,0.01984069,0.9776216],"study_design_scores_gemma":[0.0001330706,0.00005457046,0.000001721439,0.0008370803,0.0002559728,0.0002123873,0.000007824166,9.008693e-7,0.0004011,0.000004944759,0.9978699,0.0002204929],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003140456,0.9965401,0.00001412327,0.00002215277,0.0002938007,0.0002776467,0.00002763919,0.000009292725,0.002501188],"genre_scores_gemma":[0.00005422571,0.9939739,0.0000299693,0.0002929022,0.0006307994,0.00004307512,0.0001044523,0.00004151286,0.004829215],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9780293,"threshold_uncertainty_score":0.6254981,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2980937306","doi":"10.1038/s41375-019-0602-x","title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":463,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; TG Therapeutics; Astellas Pharma; BeiGene; Gilead Sciences; GlaxoSmithKline; Pharmacyclics; Genentech; Sunesis; Teva Pharmaceutical Industries; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Ibrutinib; Chlorambucil; Internal medicine; Neutropenia; Medicine; Chronic lymphocytic leukemia; IGHV@; Adverse effect; Hematology; Oncology; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","retraction":null,"screen_n_in":null,"score":{"opus":0.0243989745233313,"gpt":0.3168264164823156,"spread":0.2924274419589843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002193253,0.0002091837,0.0005847287,0.00006154819,0.00005246209,0.00001113099,0.0001870846,0.00009138399,0.00008288454],"category_scores_gemma":[0.0001721415,0.0001284107,0.0001005842,0.0001788886,0.0001491461,0.00004853412,0.00009929555,0.0001155685,0.000009113764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003739966,"about_ca_system_score_gemma":0.001444819,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001433717,"about_ca_topic_score_gemma":0.0003807659,"domain_scores_codex":[0.9982374,0.0000579463,0.0004463586,0.0004089837,0.0005398833,0.0003094834],"domain_scores_gemma":[0.9976087,0.001106641,0.0001891281,0.0007978646,0.0001754296,0.0001222436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05682265,0.004078681,0.8651747,0.0003437853,0.001445297,0.00006136527,0.005701291,0.00005485595,0.0003283714,0.00001816805,0.0004389305,0.06553192],"study_design_scores_gemma":[0.3759435,0.01414117,0.60457,0.0004189527,0.0005201485,0.000004937047,0.000257434,0.001004804,0.001452912,0.000007923651,0.001504555,0.0001737022],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951472,0.0002307342,0.00002207595,0.00009081201,0.0000965056,0.00407856,0.0002379442,0.00001910553,0.0000770847],"genre_scores_gemma":[0.9988234,0.00009644711,0.0001266333,0.00004111513,0.0000708034,0.00006388657,0.000217699,0.00004358712,0.0005164346],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3191208,"threshold_uncertainty_score":0.9779882,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2047597898","doi":"10.1038/leu.2014.30","title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":449,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Nova Scotia Cancer Centre; BC Children's Hospital; University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Medicine; Minimal residual disease; Imatinib; Internal medicine; Chemotherapy; Cohort; Imatinib mesylate; Acute lymphocytic leukemia; Oncology; Induction chemotherapy; Philadelphia chromosome; Leukemia; Lymphoblastic Leukemia; Chromosomal translocation; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.01199791892873685,"gpt":0.2883121082159874,"spread":0.2763141892872505,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001187477,0.0008378247,0.002003513,0.001164828,0.0001704172,0.00005094275,0.0009244169,0.0007594689,0.0002448302],"category_scores_gemma":[0.0008436455,0.0007614361,0.0003885253,0.001841621,0.0004334864,0.0003262167,0.0006467639,0.001275619,0.0003016249],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0122915,"about_ca_system_score_gemma":0.004580934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000704061,"about_ca_topic_score_gemma":0.0003179992,"domain_scores_codex":[0.9932165,0.0006317437,0.001693643,0.001398474,0.001556319,0.00150337],"domain_scores_gemma":[0.9956129,0.001348041,0.0006536177,0.001342019,0.0003946368,0.0006487541],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005207927,0.00288122,0.9620854,0.0007687866,0.001573086,0.002500013,0.003805265,0.0002838474,0.008932625,0.0003712643,0.003288053,0.008302464],"study_design_scores_gemma":[0.04661838,0.007512501,0.9379175,0.0002984786,0.001510774,0.0009093565,0.0002026235,0.003031942,0.001127836,0.0001023409,0.0000279525,0.0007402649],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923341,0.0001982466,0.001075378,0.0002704103,0.0005700403,0.002739246,0.0000666611,0.0001796209,0.002566317],"genre_scores_gemma":[0.9964925,0.0002599061,0.0006177981,0.000427704,0.001063347,0.0002723449,0.0002851851,0.0001819322,0.0003992644],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04141046,"threshold_uncertainty_score":0.9994836,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163344214","doi":"10.1038/leu.2009.33","title":"New insights to the MLL recombinome of acute leukemias","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":411,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Minimal residual disease; Myeloid leukemia; Fusion gene; Chromosomal translocation; Leukemia; Gene; Acute leukemia; Cancer research; Breakpoint; Biology; Acute lymphocytic leukemia; Medicine; Lymphoblastic Leukemia; Genetics; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.01953739838454069,"gpt":0.2949568201005775,"spread":0.2754194217160368,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002805353,0.0002781371,0.0005438964,0.0002806769,0.0001111243,0.00003286413,0.000629066,0.0002126608,0.0003290717],"category_scores_gemma":[0.000159764,0.0001835138,0.0002069099,0.001012279,0.00006965495,0.0001260795,0.0001468304,0.0007194837,0.0008335914],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001931131,"about_ca_system_score_gemma":0.002409144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004986025,"about_ca_topic_score_gemma":0.00002914013,"domain_scores_codex":[0.9977074,0.00007422215,0.0005017184,0.000454097,0.0006780562,0.0005844866],"domain_scores_gemma":[0.997845,0.0001234801,0.0001147629,0.001172552,0.0001897901,0.0005544094],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001699835,0.0001274991,0.0009449093,0.00007225621,0.0005606202,0.0007438324,0.004050405,0.0001576905,0.1002642,0.006432951,0.7096139,0.1753319],"study_design_scores_gemma":[0.01252339,0.004464382,0.2120093,0.0005042045,0.0007817749,0.0008788908,0.0004171057,0.00152316,0.1373197,0.006798354,0.6217394,0.001040282],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9283035,0.0004827107,0.001445587,0.02155297,0.0003212939,0.001219401,0.00001210304,0.0001731399,0.04648934],"genre_scores_gemma":[0.9556379,0.0001887133,0.005299262,0.008087084,0.0006670685,0.00001799309,0.00003311125,0.00004678193,0.03002211],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2110644,"threshold_uncertainty_score":0.9999444,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052710970","doi":"10.1038/leu.2012.100","title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","year":2012,"lang":"en","type":"review","venue":"Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":383,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Amyloidosis Foundation","keywords":"Clinical trial; AL amyloidosis; Amyloidosis; Medicine; Drug development; Clinical research; Consensus conference; Intensive care medicine; Medical physics; Pathology; Immunoglobulin light chain; Immunology; Drug; Internal medicine; Pharmacology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.5067914328514087,"gpt":0.5326453283260147,"spread":0.02585389547460604,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0167401,0.0005393961,0.00492094,0.0001007792,0.00006870727,0.00002549172,0.0003258864,0.0009329254,0.000006363439],"category_scores_gemma":[0.04334885,0.0003141736,0.001535994,0.0001314409,0.0001524872,0.000002705004,0.000204586,0.0002704825,0.000003550296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001120171,"about_ca_system_score_gemma":0.0008582238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001187941,"about_ca_topic_score_gemma":0.00006206556,"domain_scores_codex":[0.9884139,0.001479353,0.008833487,0.0007039827,0.00016971,0.0003995707],"domain_scores_gemma":[0.9850916,0.004207766,0.009425291,0.0008842582,0.0002716196,0.0001194527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001096538,0.00008001788,0.005434399,0.01089374,0.001984354,0.00001383582,0.00003570373,0.000006991131,0.0005398863,0.00007491181,0.01390063,0.9669259],"study_design_scores_gemma":[0.001331411,0.0001704933,0.000103328,0.004662343,0.003125709,0.000180943,0.0001179666,0.00001104833,0.00075464,0.00001021733,0.9891075,0.0004244354],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00474633,0.9914161,0.00003615112,0.0002941531,0.0007054016,0.002590272,0.000146062,0.00001274986,0.00005278477],"genre_scores_gemma":[0.005593356,0.9908765,0.0008577077,0.0001758619,0.001052801,0.0008596558,0.0001533114,0.00008058651,0.0003502351],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9752069,"threshold_uncertainty_score":0.999931,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015003025","doi":"10.1038/leu.2009.26","title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Dexamethasone; Cyclophosphamide; Bortezomib; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Gastroenterology; Surgery; Toxicity; Phases of clinical research; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.06004671005117541,"gpt":0.3975095953405324,"spread":0.337462885289357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001364448,0.000256363,0.0006688042,0.000235773,0.0001605526,0.00003451868,0.00009053325,0.0002927889,0.0000309156],"category_scores_gemma":[0.006721986,0.0002162758,0.000150249,0.0003245208,0.0001206163,0.0001634442,0.00004302061,0.0004129307,0.00001065021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00045103,"about_ca_system_score_gemma":0.0005855793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004242939,"about_ca_topic_score_gemma":0.00009663782,"domain_scores_codex":[0.9975767,0.000297999,0.0007159333,0.0005873441,0.0002903101,0.0005316758],"domain_scores_gemma":[0.9969276,0.002039902,0.0001456929,0.0003722381,0.0001039872,0.0004105413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6140288,0.002409073,0.02175638,0.00002595974,0.000110327,0.0005592562,0.0002144527,0.000005900174,0.005467028,0.00002923274,0.001085516,0.354308],"study_design_scores_gemma":[0.4827249,0.01652889,0.4913576,0.0000866316,0.00008081678,0.00002755921,0.00006739226,0.001982663,0.004764685,0.0003061279,0.00187237,0.0002003215],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945288,0.0004186902,0.0001605885,0.00142777,0.000263532,0.00305512,0.00003659933,0.00007353099,0.00003538168],"genre_scores_gemma":[0.992181,0.000270131,0.005779338,0.0003842868,0.0004241666,0.0002968951,0.0001396767,0.0000285654,0.0004959198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4696012,"threshold_uncertainty_score":0.8819471,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2000069677","doi":"10.1038/leu.2009.147","title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":360,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Medicine; Placebo; Multiple myeloma; Internal medicine; Gastroenterology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.04957727320909769,"gpt":0.3301043192462646,"spread":0.2805270460371669,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008720608,0.000375961,0.001234551,0.0001710302,0.00009904275,0.00003553355,0.0001983841,0.0002007528,0.0001717675],"category_scores_gemma":[0.00230197,0.0002050481,0.0001601058,0.0002405194,0.0001372492,0.0001548936,0.00005073718,0.0005056128,0.00001260174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000771089,"about_ca_system_score_gemma":0.0004951502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001784868,"about_ca_topic_score_gemma":0.001239048,"domain_scores_codex":[0.9967149,0.0005421803,0.0008209063,0.0005486265,0.0008621254,0.0005112017],"domain_scores_gemma":[0.9960093,0.002482291,0.000374543,0.0007019367,0.0001316461,0.0003002284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2406759,0.001818214,0.6447126,0.00005963315,0.0007315143,0.0006396993,0.0008884881,0.00001548955,0.005571169,0.00001856155,0.0005741532,0.1042946],"study_design_scores_gemma":[0.1928214,0.004063403,0.7981959,0.000484238,0.0001713209,0.000003486327,0.00004323842,0.00016348,0.003727319,0.00002672931,0.0001102907,0.0001892225],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970112,0.0002867045,0.00003831524,0.0002218464,0.0001443529,0.001851997,0.000210517,0.00003696432,0.0001981151],"genre_scores_gemma":[0.9978054,0.0001382992,0.0004204459,0.0003059165,0.0001466233,0.00004228795,0.0004792441,0.00003900014,0.0006227663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1534833,"threshold_uncertainty_score":0.8361619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012153991","doi":"10.1038/sj.leu.2404609","title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"CD38; Imatinib mesylate; Myeloid leukemia; Stem cell; Haematopoiesis; Cancer research; Biology; CD34; Myeloid; breakpoint cluster region; Leukemia; Imatinib; Immunology; Cell biology; Receptor; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01218732001443293,"gpt":0.2583148605492473,"spread":0.2461275405348144,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007028898,0.0006517421,0.001023209,0.0003937408,0.000174016,0.00004132374,0.0005490136,0.0004720276,0.0002044721],"category_scores_gemma":[0.0001027455,0.0005784337,0.0003080234,0.0009419277,0.0002266442,0.0001759388,0.0002232723,0.0006991511,0.0001431706],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01633129,"about_ca_system_score_gemma":0.003565636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001023731,"about_ca_topic_score_gemma":0.002101542,"domain_scores_codex":[0.9960026,0.0001148636,0.0009459892,0.0008974338,0.000900808,0.001138333],"domain_scores_gemma":[0.9968264,0.0005161409,0.0003774353,0.00140549,0.0003393861,0.0005351189],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002651391,0.000184284,0.006975203,0.001113267,0.0007836258,0.0006361609,0.003475689,0.000547802,0.9255753,0.0006555847,0.0221893,0.03521243],"study_design_scores_gemma":[0.007052118,0.0006230792,0.06001464,0.0007790599,0.0001780664,0.00006704868,0.0006852782,0.00006251096,0.8931037,0.0001028973,0.03673928,0.0005923291],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806381,0.007542918,0.0008150103,0.0004141442,0.0005178191,0.001784714,0.00009549234,0.0003439856,0.007847806],"genre_scores_gemma":[0.9699125,0.0003080189,0.006044204,0.0006018627,0.0004496383,0.00007397478,0.00007819103,0.0001489406,0.02238264],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05303943,"threshold_uncertainty_score":0.9996667,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990020715","doi":"10.1038/leu.2008.84","title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Imatinib; Chronic myelogenous leukemia; Internal medicine; Gastroenterology; Neutropenia; Imatinib mesylate; Leukemia; Oncology; Chemotherapy; Myeloid leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.02218488206773787,"gpt":0.2795651517636827,"spread":0.2573802696959449,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002927289,0.0007821849,0.001194797,0.0006485727,0.0002267891,0.00003737899,0.0004446103,0.0002918322,0.0002551586],"category_scores_gemma":[0.0002308002,0.0005807923,0.00007777153,0.001984326,0.0003386978,0.000302646,0.0001079095,0.0008288924,0.0001451407],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0498163,"about_ca_system_score_gemma":0.02106473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001511332,"about_ca_topic_score_gemma":0.01588229,"domain_scores_codex":[0.9951293,0.0002026025,0.001020871,0.001284744,0.0009952936,0.001367209],"domain_scores_gemma":[0.9974329,0.0002743134,0.000339398,0.001320961,0.0001990906,0.0004332667],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1356671,0.002358692,0.7639591,0.002307049,0.0007172332,0.0135586,0.0128595,0.01965971,0.02420533,0.00004948822,0.002546641,0.0221115],"study_design_scores_gemma":[0.09871811,0.01114966,0.8609933,0.004171972,0.0001386833,0.0003550293,0.0001532502,0.0005484587,0.01937132,0.00001316407,0.003122435,0.00126462],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944185,0.001202267,0.00004533644,0.0001589529,0.00007591945,0.002917719,0.00005784352,0.00014279,0.0009806454],"genre_scores_gemma":[0.990761,0.0002288912,0.003957496,0.0004106836,0.0001674616,0.0006383552,0.0001247041,0.0001622736,0.003549082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09703418,"threshold_uncertainty_score":0.9996644,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2625253716","doi":"10.1038/leu.2017.138","title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","year":2017,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":354,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; McGill University Health Centre","funders":"Janssen Pharmaceuticals","keywords":"Multiple myeloma; Medicine; Internal medicine; Carfilzomib; Oncology; Proteasome inhibitor; Lenalidomide; Refractory (planetary science); Hematology; Natural history; Pomalidomide; Bortezomib; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01825545139266853,"gpt":0.293698689027516,"spread":0.2754432376348475,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002864379,0.0002380055,0.0004473811,0.0001868475,0.0001567614,0.00003032895,0.0002302972,0.00009816822,0.00004975686],"category_scores_gemma":[0.0004769954,0.0001924958,0.0001005858,0.00004015762,0.0002089762,0.0002440816,0.0002622742,0.0003546265,0.00005163478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002151622,"about_ca_system_score_gemma":0.0005314268,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001349471,"about_ca_topic_score_gemma":0.00007141929,"domain_scores_codex":[0.9982309,0.00008422496,0.0003477901,0.0004439914,0.0005202277,0.0003728945],"domain_scores_gemma":[0.9981385,0.00005869199,0.0002100171,0.001097922,0.000162458,0.0003323347],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008658757,0.00238093,0.6440898,0.0005987409,0.001182372,0.0009841169,0.01888959,0.000001090175,0.2050663,0.00001756633,0.009565456,0.1085653],"study_design_scores_gemma":[0.01158385,0.001251831,0.9746183,0.0002790659,0.00008262097,0.000012721,0.000548155,0.000150109,0.003036104,0.000004803076,0.008232309,0.000200177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942818,0.001264949,0.0000010452,0.0001484605,0.0004378142,0.002065084,0.000007706612,0.00004338324,0.001749818],"genre_scores_gemma":[0.9901871,0.00001654073,0.0004038933,0.00009736788,0.0001558572,0.0001468968,0.00001015976,0.00003858518,0.008943603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3305285,"threshold_uncertainty_score":0.7849751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2530614832","doi":"10.1038/leu.2016.275","title":"Isocitrate dehydrogenase mutations in myeloid malignancies","year":2016,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; Celgene","keywords":"IDH2; Isocitrate dehydrogenase; Biology; Myeloid leukemia; IDH1; Myeloid; Cancer research; Myelodysplastic syndromes; Epigenetics; Histone; Mutation; Genetics; Gene; Biochemistry; Enzyme; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.04582845719732767,"gpt":0.3516455735021188,"spread":0.3058171163047911,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005611064,0.0006871701,0.002390474,0.0008633948,0.0001011227,0.00005083349,0.0004818346,0.0008335818,0.0006249361],"category_scores_gemma":[0.0004548281,0.0004787372,0.0007410391,0.001135439,0.0002819952,0.000142237,0.0001939504,0.001336829,0.003916742],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0073331,"about_ca_system_score_gemma":0.00874381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000123688,"about_ca_topic_score_gemma":0.00004210253,"domain_scores_codex":[0.9962277,0.0002723512,0.00108827,0.0008354521,0.0005775248,0.0009987231],"domain_scores_gemma":[0.9976674,0.0005137438,0.0003083895,0.0009770433,0.0001441356,0.000389301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003041109,0.00005277294,0.00003258518,0.01581615,0.0003016045,0.001982425,0.0001397163,0.000001544255,0.00006523934,0.0005729954,0.006597862,0.9744067],"study_design_scores_gemma":[0.001257614,0.00007845744,0.00002499895,0.02563838,0.0004305876,0.0006020453,0.00003196555,0.00001994404,0.00005422909,0.0001422718,0.9712223,0.000497152],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004749699,0.9895899,0.00003840054,0.0001946132,0.0001612077,0.001741336,0.0001653771,0.0001547024,0.007479501],"genre_scores_gemma":[0.00007103768,0.9827378,0.0004905657,0.0002425095,0.0004860297,0.000619101,0.0003786603,0.0001909177,0.01478339],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9739096,"threshold_uncertainty_score":0.9997664,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1969986792","doi":"10.1038/sj.leu.2403184","title":"Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells ‘hide out’ in the bone marrow","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Blood Services; University of Alberta","funders":"National Heart, Lung, and Blood Institute","keywords":"Stem cell; Homing (biology); Biology; Bone marrow; Haematopoiesis; Adult stem cell; Stem cell transplantation for articular cartilage repair; Stem cell marker; Amniotic stem cells; Neural stem cell; CXCR4; Cell biology; Mesenchymal stem cell; Transdifferentiation; Clinical uses of mesenchymal stem cells; Neurosphere; Endothelial stem cell; Immunology; Chemokine; In vitro; Inflammation","retraction":null,"screen_n_in":null,"score":{"opus":0.03006819874957416,"gpt":0.2694272485135339,"spread":0.2393590497639598,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008547425,0.0002981073,0.0004765208,0.0001574556,0.0001821151,0.0001347332,0.0001978514,0.0001980217,0.00008342173],"category_scores_gemma":[0.00009502353,0.0002200152,0.0001214514,0.0002222865,0.0001442003,0.0001617739,0.00007943571,0.0006743349,0.00005487937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003534729,"about_ca_system_score_gemma":0.0001796614,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002210082,"about_ca_topic_score_gemma":0.00002998625,"domain_scores_codex":[0.9972616,0.0004170601,0.0004405424,0.0005654387,0.0005926091,0.0007227265],"domain_scores_gemma":[0.9977399,0.00134871,0.00013799,0.0003844743,0.0001299228,0.0002590572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007946243,0.0002374942,0.004862464,0.001536417,0.00004479093,0.001295216,0.008851962,0.0001218225,0.9609621,0.0001276939,0.007717795,0.01344761],"study_design_scores_gemma":[0.008581704,0.001423708,0.04381404,0.001111978,0.0002722105,0.0001352616,0.002258433,0.01129169,0.9168143,0.00008896825,0.01333462,0.0008730693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871528,0.001172476,0.0006306869,0.0000976419,0.0001299425,0.001653628,0.0000331865,0.00003054376,0.009099097],"genre_scores_gemma":[0.9930467,0.000123697,0.001065984,0.0004773111,0.0001473754,0.00006107255,0.000007461198,0.00004953991,0.005020863],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0441478,"threshold_uncertainty_score":0.8971961,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2052739233","doi":"10.1038/leu.2014.229","title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; Hôpital Maisonneuve-Rosemont; Alberta Cancer Foundation; Hamilton Health Sciences; Dalhousie University; CancerCare Manitoba; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Regimen; Young adult; Confidence interval; Pediatrics; Internal medicine; Lymphoblastic Leukemia; Acute lymphocytic leukemia; Leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.01821218232353751,"gpt":0.2860786902423308,"spread":0.2678665079187933,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006673695,0.0006944834,0.001479901,0.0005655007,0.0001577123,0.00006947729,0.000746051,0.0005196862,0.0001440575],"category_scores_gemma":[0.001033217,0.0005826006,0.0004171415,0.000844644,0.0003522528,0.00025151,0.0002222392,0.0005320331,0.0001401724],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004901753,"about_ca_system_score_gemma":0.003456619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005298445,"about_ca_topic_score_gemma":0.000172842,"domain_scores_codex":[0.9947857,0.0001623252,0.001182537,0.001118123,0.001421027,0.001330306],"domain_scores_gemma":[0.9949756,0.001731718,0.0006229546,0.001502209,0.0004161739,0.0007513575],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02634196,0.0007577465,0.9016852,0.004942333,0.002402467,0.002512476,0.003855272,0.0009177973,0.01997554,0.0004419196,0.02663998,0.009527303],"study_design_scores_gemma":[0.1233121,0.005648293,0.8451903,0.00110443,0.003291923,0.0004846417,0.0002097437,0.01317224,0.004996987,0.0001138518,0.0008703464,0.001605089],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985092,0.00009780452,0.01098155,0.0001644375,0.0002746143,0.002398182,0.0001052081,0.0002981271,0.0005880085],"genre_scores_gemma":[0.9883067,0.00008091462,0.007215102,0.0004901248,0.0009991939,0.0004044016,0.0002425874,0.0002515713,0.002009388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09697016,"threshold_uncertainty_score":0.9996625,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1972467214","doi":"10.1038/leu.2009.253","title":"Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre hospitalier universitaire de Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Vincristine; Chemotherapy; Asparaginase; Cancer; Internal medicine; Acute lymphocytic leukemia; Pediatrics; Clinical trial; Surgery; Leukemia; Lymphoblastic Leukemia; Cyclophosphamide","retraction":null,"screen_n_in":null,"score":{"opus":0.02372343446026951,"gpt":0.3262741725191292,"spread":0.3025507380588596,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004327193,0.0008110474,0.00138703,0.0004203421,0.0001897621,0.00009133848,0.0007746557,0.0005244486,0.00007750688],"category_scores_gemma":[0.0005403974,0.0006342902,0.0003266135,0.0008204313,0.0006777775,0.000451582,0.0001415084,0.0005884483,0.00005471765],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.0090531,"about_ca_system_score_gemma":0.01427241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001445918,"about_ca_topic_score_gemma":0.0004771451,"domain_scores_codex":[0.9944847,0.00008775797,0.001339556,0.001292691,0.001313836,0.001481428],"domain_scores_gemma":[0.9959986,0.0003996231,0.0006636875,0.001490987,0.000687053,0.0007601032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1550549,0.003993458,0.2724283,0.004297953,0.01635792,0.007646265,0.005928987,0.0187009,0.1197536,0.002348029,0.2237713,0.1697184],"study_design_scores_gemma":[0.1383103,0.007795238,0.7940944,0.003763782,0.00269381,0.001389405,0.00003991594,0.004922247,0.03673897,0.0001723834,0.008269753,0.001809777],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9559283,0.0001573228,0.004371057,0.001235618,0.0002286888,0.03442824,0.000805778,0.0003322653,0.002512712],"genre_scores_gemma":[0.9710331,0.0002144278,0.006134881,0.002898356,0.001028916,0.01220284,0.001022899,0.0002107459,0.005253853],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5216661,"threshold_uncertainty_score":0.9996108,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015678735","doi":"10.1038/leu.2013.337","title":"The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","year":2013,"lang":"en","type":"review","venue":"Leukemia","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":283,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"Biology; Haematopoiesis; Myeloid; Chromosomal translocation; Lymphopoiesis; Stem cell; Molecular biology; Cancer research; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01791343929479344,"gpt":0.2852960887300804,"spread":0.267382649435287,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001853391,0.000323276,0.0005737402,0.00006111874,0.0001269454,0.00008462165,0.0002779796,0.0003461193,0.000009233587],"category_scores_gemma":[0.00009302182,0.0002213586,0.0001971813,0.0001441452,0.0001140095,0.000003586857,0.00008949686,0.000161649,0.00002167605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007952093,"about_ca_system_score_gemma":0.0003738762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004421822,"about_ca_topic_score_gemma":0.000053842,"domain_scores_codex":[0.9984791,0.0001514769,0.0005057906,0.0004443211,0.0001417426,0.0002775352],"domain_scores_gemma":[0.9990258,0.0001035522,0.0001876218,0.0005347954,0.00004648041,0.0001017136],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000004547246,0.00002272922,0.00006375086,0.002317193,0.00009498053,0.000003514008,0.00003751716,0.000007551595,0.0006741192,0.0001182577,0.0002974959,0.9963583],"study_design_scores_gemma":[0.0002215371,0.00004282635,0.0001028794,0.0008692386,0.0001604486,0.00001401298,0.00002198919,0.00001719049,0.001651395,0.0005135396,0.9960088,0.000376189],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002137726,0.9967432,0.0001591727,0.00004008873,0.00009657309,0.0006288388,0.00002782341,0.000009209016,0.0001573572],"genre_scores_gemma":[0.001550106,0.9969468,0.0001883752,0.00001922354,0.0001724457,0.000309548,0.000258823,0.00005259414,0.0005021092],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9959822,"threshold_uncertainty_score":0.9026742,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2345645288","doi":"10.1038/leu.2015.233","title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group","year":2015,"lang":"en","type":"review","venue":"Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":272,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Transplantation; Myelofibrosis; Alemtuzumab; Stem cell; Hematopoietic stem cell transplantation; Internal medicine; Cytopenia; Oncology; Immunology; Bone marrow","retraction":null,"screen_n_in":null,"score":{"opus":0.03782294263671929,"gpt":0.3153776842246661,"spread":0.2775547415879468,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002722812,0.0003333148,0.0009693035,0.0002524214,0.00002787759,0.00002397297,0.0001233747,0.0002312874,0.00001120916],"category_scores_gemma":[0.000001673946,0.0002756255,0.00008837009,0.0002140762,0.0000512975,0.00005576048,0.00002676686,0.0001974679,0.000006551216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009567175,"about_ca_system_score_gemma":0.0003180229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000207418,"about_ca_topic_score_gemma":0.00001316665,"domain_scores_codex":[0.9981171,0.0001183065,0.0006797559,0.0004999803,0.0004043498,0.0001804935],"domain_scores_gemma":[0.9990973,0.00006467792,0.0004530895,0.0002007102,0.00006408012,0.0001200796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001493202,0.0003657792,0.005183383,0.03431657,0.0003763497,0.0001181562,0.000550688,0.000004833362,0.00001216168,0.00007779121,0.0001373049,0.9587077],"study_design_scores_gemma":[0.02301148,0.002665417,0.04206384,0.1864016,0.01337275,0.0008313766,0.001345784,0.0002256248,0.0008883525,0.0001584405,0.7265682,0.002467107],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04013526,0.9549761,0.00003045538,0.00003215676,0.0001030259,0.002450508,0.0001158752,0.00002968774,0.002126964],"genre_scores_gemma":[0.01872499,0.977085,0.0006039014,0.00004939239,0.0000464393,0.000983538,0.0023429,0.00004125802,0.0001225951],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9562405,"threshold_uncertainty_score":0.9999696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2908744276","doi":"10.1038/s41375-018-0351-2","title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","year":2019,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"Medical Research Council; National Institute of Diabetes and Digestive and Kidney Diseases; Blood Cancer UK; Deutsche Forschungsgemeinschaft; National Cancer Institute; Washington University in St. Louis; Vanderbilt University; National Institute for Health and Care Research; Associazione Italiana per la Ricerca sul Cancro; Celgene","keywords":"Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Monosomy; Karyotype; Biology; Oncology; Chromosome 7 (human); Genetics; Medicine; Chromosome; Bone marrow; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01787749074314261,"gpt":0.2753827537101337,"spread":0.2575052629669911,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002436928,0.0003894188,0.0006026832,0.0002876187,0.0001604849,0.00009502913,0.0002441709,0.0001627452,0.0008092702],"category_scores_gemma":[0.0005191443,0.0002928454,0.00009227268,0.0006422842,0.0002835987,0.0002347276,0.000150525,0.0005305617,0.001367504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00198819,"about_ca_system_score_gemma":0.001362258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007053813,"about_ca_topic_score_gemma":0.0002531776,"domain_scores_codex":[0.9970568,0.0001063721,0.0004070989,0.0006748218,0.0008797717,0.0008751194],"domain_scores_gemma":[0.9978065,0.0007490672,0.0001476693,0.0006304902,0.0002446223,0.0004216203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001603174,0.0001547783,0.971988,0.001439447,0.0004109018,0.001266689,0.001218228,0.0003547427,0.007338852,0.001225923,0.003219278,0.009780047],"study_design_scores_gemma":[0.00476724,0.002014955,0.9744233,0.0004898484,0.0002720272,0.0007785914,0.0003747453,0.009795966,0.0007331371,0.0004282929,0.005434689,0.0004872131],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893731,0.0001640095,0.000806413,0.0004363204,0.0001333728,0.001391094,0.00002250721,0.0002763481,0.007396808],"genre_scores_gemma":[0.9925908,0.00002567593,0.003793968,0.0002440605,0.0001545722,0.0001049045,0.0005427871,0.0001028715,0.002440394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009441223,"threshold_uncertainty_score":0.9999524,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2216303864","doi":"10.1038/leu.2015.356","title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","year":2015,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":255,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of Alberta","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Transplantation; Disease; Oncology; Internal medicine; Intensive care medicine; Autologous stem-cell transplantation","retraction":null,"screen_n_in":null,"score":{"opus":0.08944497331140153,"gpt":0.362895462239456,"spread":0.2734504889280545,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004173575,0.0003158646,0.001110981,0.0002429522,0.00006469509,0.00001558645,0.0006194506,0.0002087884,0.0001044873],"category_scores_gemma":[0.0001391521,0.0002021292,0.0005730516,0.0005009936,0.0001120892,0.00004805196,0.0004722106,0.0004444618,0.00005653378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001348274,"about_ca_system_score_gemma":0.0005067301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006346861,"about_ca_topic_score_gemma":0.00001793425,"domain_scores_codex":[0.9975465,0.0001461829,0.0008359912,0.0003716438,0.0008118264,0.0002878769],"domain_scores_gemma":[0.9980274,0.0002144394,0.0006114122,0.0008315622,0.0001665159,0.0001486219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006972965,0.0001577771,0.0005614338,0.005010401,0.001524638,0.00007050076,0.00004329097,7.509744e-7,0.000002574817,0.0004470734,0.003459428,0.9886524],"study_design_scores_gemma":[0.0024653,0.00007569901,0.001080179,0.0192288,0.0009179011,0.00005043527,0.00006011079,0.00006758123,0.00001613033,0.00004531342,0.9758472,0.000145391],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002694066,0.9646622,0.00005304,0.0002574478,0.0010441,0.002751925,0.0001953009,0.0000501837,0.0307164],"genre_scores_gemma":[0.003633565,0.9861404,0.00375914,0.00002197814,0.0001592934,0.0002478416,0.0007327816,0.00006293059,0.005242022],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.988507,"threshold_uncertainty_score":0.824259,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985337146","doi":"10.1038/leu.2010.53","title":"Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex","year":2010,"lang":"en","type":"article","venue":"Leukemia","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":254,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; European Commission; National Cancer Institute; National Institutes of Health; University of Alberta","keywords":"Haematopoiesis; Progenitor cell; Bone marrow; Cell biology; Stem cell; Chemotaxis; Stromal cell; Biology; Sphingosine-1-phosphate; Immunology; Chemistry; Biochemistry; Sphingosine; Cancer research; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02325974615285232,"gpt":0.240985131938287,"spread":0.2177253857854347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002514078,0.0002625968,0.0003606866,0.00005256849,0.000148433,0.00004816915,0.0002913557,0.0001519067,0.00002257954],"category_scores_gemma":[0.00002627412,0.0001905227,0.00007101814,0.000223838,0.00007864865,0.00002639271,0.0001351126,0.0001615767,5.900825e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000384836,"about_ca_system_score_gemma":0.0001221111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008229063,"about_ca_topic_score_gemma":0.000461135,"domain_scores_codex":[0.9984642,0.00007845339,0.0005077313,0.0004213993,0.0002896839,0.0002385149],"domain_scores_gemma":[0.9988936,0.0000990953,0.0003495591,0.0004163006,0.0001587485,0.00008265845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001744363,0.0001598526,0.003349573,0.000251718,0.00005082691,0.000001833053,0.003106978,0.0009494452,0.991734,0.00001783762,0.0000199102,0.0001836284],"study_design_scores_gemma":[0.001842124,0.00005086443,0.01507386,0.0001170201,0.00006754392,0.0000158375,0.0007171197,0.00265698,0.9790425,0.000002170353,0.0002066173,0.0002074034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978749,0.000527262,0.0003362006,0.00008618284,0.0001137965,0.0009136543,0.0001265781,0.00001037743,0.00001104446],"genre_scores_gemma":[0.9987972,0.00007466699,0.0005972935,0.0001371675,0.0001318002,0.00007985679,0.0000942262,0.00003856243,0.00004918759],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01269151,"threshold_uncertainty_score":0.7769291,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2794594588","doi":"10.1038/s41375-018-0117-x","title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer","year":2018,"lang":"en","type":"review","venue":"Leukemia","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; Walloon excellence in life sciences and biotechnology; Fonds De La Recherche Scientifique - FNRS; Austrian Science Fund; Ludwig Institute for Cancer Research","keywords":"STAT5; Chromatin remodeling; Biology; Cancer research; Chromatin; Transcription factor; Cell biology; STAT3; JAK-STAT signaling pathway; Histone; Signal transduction; Genetics; Gene; Receptor tyrosine kinase","retraction":null,"screen_n_in":null,"score":{"opus":0.06830776827759728,"gpt":0.3666206695964007,"spread":0.2983129013188034,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001857692,0.0002139404,0.0008402577,0.000264498,0.00005525996,0.00001654305,0.00004661291,0.0001574037,0.00007594641],"category_scores_gemma":[0.00006046503,0.0001802585,0.00009325879,0.0002192031,0.00006155064,0.00004636227,0.00003224015,0.0002655923,0.000003728835],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004327875,"about_ca_system_score_gemma":0.0004395664,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002336546,"about_ca_topic_score_gemma":0.00003701342,"domain_scores_codex":[0.998682,0.00004603612,0.0006533226,0.0003383762,0.0001263488,0.0001539209],"domain_scores_gemma":[0.9990608,0.0001589962,0.0003390412,0.0002748842,0.00009205152,0.00007426165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000067468,0.0001087133,0.0001425471,0.03160463,0.0002404362,0.000008551267,0.001247195,0.0003291217,0.01646064,0.0008659663,0.0009319025,0.9479928],"study_design_scores_gemma":[0.003889566,0.001331197,0.002166426,0.3015713,0.003983163,0.000946348,0.0002971118,0.01079176,0.01052943,0.003047883,0.6596411,0.001804788],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03337037,0.9648497,0.0004098079,0.00007386768,0.00007275443,0.0007102987,0.0001093458,0.00002791625,0.0003760093],"genre_scores_gemma":[0.0173125,0.9805341,0.001549759,0.00005293492,0.0001810289,0.00008839805,0.0001384511,0.00004729091,0.00009558298],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.946188,"threshold_uncertainty_score":0.7350727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2884362356","doi":"10.1038/s41375-018-0210-1","title":"Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":247,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health; Servier; Astex Pharmaceuticals; Astellas Pharma; Gilead Sciences; Ablynx; Teva Pharmaceutical Industries; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Tolerability; Gastroenterology; Peripheral edema; Nausea; Discontinuation; Adverse effect; Refractory (planetary science); Minimal residual disease; Progressive disease; Leukemia; Surgery; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.009278922816624076,"gpt":0.2184857901486672,"spread":0.2092068673320432,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003461013,0.0003579937,0.0004242821,0.0002412001,0.0002537864,0.00002847784,0.0005398818,0.0006672259,0.002384001],"category_scores_gemma":[0.00007059163,0.0003402382,0.0001422067,0.0003041813,0.0003413794,0.000162293,0.0001949099,0.0009002268,0.007163777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067268,"about_ca_system_score_gemma":0.0005767366,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007174623,"about_ca_topic_score_gemma":0.0003652021,"domain_scores_codex":[0.9977819,0.0002025438,0.0005329463,0.0005958413,0.00007195336,0.00081483],"domain_scores_gemma":[0.9988539,0.0001029715,0.0001750478,0.0007463582,0.00007162856,0.00005006626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002347457,0.0001237029,0.0008300125,0.00002309444,0.00003875637,0.0000476186,0.000888514,0.00001017855,0.9693164,0.00113375,0.02069375,0.00665951],"study_design_scores_gemma":[0.005524439,0.0009039047,0.01145625,0.00009342743,0.00003198289,0.00007274825,0.0004975153,0.00007210775,0.6992726,0.0009529518,0.2804376,0.0006844208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648455,0.001736791,0.000189782,0.00007125736,0.002350972,0.0003377992,0.00002320837,0.0002066901,0.03023797],"genre_scores_gemma":[0.9791107,0.00008056883,0.0004876206,0.0007230089,0.0001815934,0.00004991251,0.00005373853,0.00005901741,0.01925387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2700437,"threshold_uncertainty_score":0.999905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3004303031","doi":"10.1038/s41375-020-0711-6","title":"Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development; Raymond and Beverly Sackler Institute for Biological, Physical and Engineering Sciences, Yale University; Yale University","keywords":"Lenalidomide; Medicine; Internal medicine; Daratumumab; Dexamethasone; Multiple myeloma; Population; Gastroenterology; Refractory (planetary science); Oncology; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.06341334890599047,"gpt":0.3557824096760606,"spread":0.2923690607700701,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000958133,0.0003953854,0.001859887,0.0002478707,0.0001124098,0.0000596781,0.0003426391,0.0001599966,0.0001297659],"category_scores_gemma":[0.003366132,0.0003130571,0.0001276394,0.0005620002,0.0002678699,0.0002203456,0.0004087629,0.0005933168,0.00003325572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005847837,"about_ca_system_score_gemma":0.0007967549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002124854,"about_ca_topic_score_gemma":0.0003979839,"domain_scores_codex":[0.9965183,0.0006363182,0.0008775212,0.00075897,0.0006443723,0.0005644972],"domain_scores_gemma":[0.9974411,0.00100166,0.0002576072,0.0005500219,0.0001342361,0.0006153783],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9005759,0.005241921,0.01792486,0.0003485853,0.001500156,0.003102618,0.007194368,0.00001152867,0.02307375,0.00006675298,0.0008346994,0.04012483],"study_design_scores_gemma":[0.9719147,0.003768263,0.008041672,0.0001869162,0.0003279216,0.00003710146,0.001300059,0.01031934,0.003526323,0.00004916497,0.0002539573,0.0002745823],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913469,0.001599543,0.000102688,0.0004448014,0.00009652349,0.005102959,0.00005833755,0.00005466019,0.001193616],"genre_scores_gemma":[0.9963413,0.0001593793,0.001893096,0.0002959394,0.00007855,0.0003780027,0.00006542215,0.00006021643,0.0007281235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07133877,"threshold_uncertainty_score":0.9999322,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086061986","doi":"10.1038/leu.2013.350","title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","year":2013,"lang":"en","type":"review","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":232,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"National Cancer Institute","keywords":"Daratumumab; Lenalidomide; Medicine; Multiple myeloma; Combination therapy; Cancer research; Panobinostat; Pharmacology; Histone deacetylase; Immunology; Biology; Histone","retraction":null,"screen_n_in":null,"score":{"opus":0.08683142709177934,"gpt":0.3427305704482578,"spread":0.2558991433564785,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000424211,0.0003971125,0.001223927,0.0003649127,0.00004108691,0.00005364937,0.0003184392,0.0003737457,0.0001798885],"category_scores_gemma":[0.0003611047,0.0002655809,0.0002304807,0.0003645804,0.00005621555,0.0001276101,0.0002473729,0.0007613311,0.00004201317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00128252,"about_ca_system_score_gemma":0.000756759,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01790907,"about_ca_topic_score_gemma":0.002777833,"domain_scores_codex":[0.9973177,0.00009881006,0.0009426127,0.0006172389,0.0006518263,0.0003717889],"domain_scores_gemma":[0.9980356,0.0006729973,0.0005058069,0.0005451404,0.00005551333,0.0001849077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001070018,0.0000858791,0.002893908,0.0007006409,0.0003061405,0.0003809271,0.0001614911,6.41624e-7,0.0001950107,0.00008434146,0.0006782489,0.9944057],"study_design_scores_gemma":[0.01518573,0.000243829,0.0654145,0.04648445,0.0007524159,0.001354661,0.0004700694,0.001957576,0.0002592198,0.001365141,0.8655798,0.0009326347],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01250218,0.9798979,0.001605797,0.0003657151,0.0007683939,0.003802071,0.00008760274,0.0000557706,0.0009146133],"genre_scores_gemma":[0.01835936,0.9709096,0.00763092,0.00006189375,0.000446421,0.0003523121,0.0009970973,0.00008077182,0.001161608],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9934731,"threshold_uncertainty_score":0.9999796,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2582892663","doi":"10.1038/leu.2017.30","title":"Biological and clinical consequences of NPM1 mutations in AML","year":2017,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"NPM1; Myeloid leukemia; Haematopoiesis; Mutation; Leukemia; Myeloid; Cancer research; Bone marrow; Gene mutation; Biology; Gene; Medicine; Stem cell; Immunology; Genetics; Karyotype","retraction":null,"screen_n_in":null,"score":{"opus":0.2722373400079822,"gpt":0.4954348384625376,"spread":0.2231974984545554,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001147122,0.0002836195,0.002496124,0.0002897927,0.00006063911,0.0000234403,0.0003569417,0.0008453494,0.0001285239],"category_scores_gemma":[0.002926439,0.0001890419,0.0003775111,0.000195671,0.001928688,0.00004708607,0.0002093885,0.00131928,0.00009907725],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006425878,"about_ca_system_score_gemma":0.004484681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001856942,"about_ca_topic_score_gemma":0.00003053343,"domain_scores_codex":[0.9973897,0.0003888675,0.001148833,0.0005174517,0.0002299213,0.0003252558],"domain_scores_gemma":[0.9972091,0.00135432,0.0004960977,0.0006461107,0.00009069253,0.0002036868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003012274,0.00004183238,0.002477443,0.004066121,0.0001582948,0.0004219401,0.00002497984,4.725084e-8,0.000002960138,0.0001851709,0.0005469715,0.9920441],"study_design_scores_gemma":[0.001168092,0.0003549516,0.002967714,0.01072334,0.000459891,0.0004775724,0.00002961753,0.0000134105,0.000003275243,0.0002450622,0.9833277,0.0002293428],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003441639,0.9914052,0.000004122586,0.000139076,0.0001116964,0.0009529594,0.00005815796,0.00001775347,0.00386941],"genre_scores_gemma":[0.00115143,0.996933,0.0007073065,0.00004276961,0.0001917797,0.00005574894,0.0001434703,0.00002525215,0.0007492325],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9918148,"threshold_uncertainty_score":0.7955632,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2026214119","doi":"10.1038/sj.leu.2404856","title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma","year":2007,"lang":"en","type":"article","venue":"Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; Lymphoma Research Foundation; U.S. Department of Health and Human Services","keywords":"BCL6; Diffuse large B-cell lymphoma; Biology; Lymphoma; Chromosomal translocation; Cancer research; Germinal center; B cell; Molecular biology; Gene; Genetics; Immunology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.01082582329923507,"gpt":0.2351289231680874,"spread":0.2243030998688523,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008842604,0.0001392972,0.0002898218,0.00009445773,0.00002701066,0.000005303754,0.00003223859,0.00005871388,0.00003212771],"category_scores_gemma":[0.00002251031,0.0000930376,0.00007209581,0.00007786489,0.00008476664,0.00003139302,0.00003039233,0.00003900298,0.000001239496],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002966521,"about_ca_system_score_gemma":0.0001020581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000403214,"about_ca_topic_score_gemma":0.0002768015,"domain_scores_codex":[0.9991891,0.00002729462,0.0002903535,0.0001831869,0.0001427924,0.0001672739],"domain_scores_gemma":[0.9994351,0.0001806497,0.0001014433,0.0001527874,0.00005316295,0.00007691031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002122209,0.003465318,0.9579533,0.0001129822,0.00009395093,0.0001137489,0.0008249391,0.000003300394,0.03217045,0.002840349,0.00002470118,0.002184706],"study_design_scores_gemma":[0.009021899,0.0001976779,0.7882574,0.00009739162,0.00004590828,0.00002088397,0.0003688669,0.00009929202,0.2015901,0.0001929219,0.00004118272,0.00006645281],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971066,0.0003530591,0.001560939,0.00009897138,0.00004842064,0.0002277196,0.0000992836,0.000008747862,0.0004963159],"genre_scores_gemma":[0.9995975,0.00005269409,0.00005409947,0.0001107205,0.00002612823,0.00002388452,0.00008240661,0.000008723935,0.00004378238],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1696959,"threshold_uncertainty_score":0.3793963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2026048257","doi":"10.1038/sj.leu.2402196","title":"Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells","year":2001,"lang":"en","type":"article","venue":"Leukemia","topic":"Plant biochemistry and biosynthesis","field":"Biochemistry, Genetics and Molecular Biology","cited_by":214,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; Institute for Biological Sciences; University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Medical Research Council; University of Pennsylvania","keywords":"Lovastatin; Geranylgeranylation; Farnesyl pyrophosphate; Geranylgeranyl pyrophosphate; Mevalonic acid; Mevalonate pathway; Farnesyl-diphosphate farnesyltransferase; Biology; Apoptosis; Farnesol; Dolichol; Farnesyltransferase inhibitor; Geranylgeraniol; Myeloid leukemia; HMG-CoA reductase; Hydroxymethylglutaryl-CoA reductase; Biochemistry; Pharmacology; Cancer research; Prenylation; Cholesterol; Farnesyltransferase; Reductase; Enzyme; ATP synthase; Biosynthesis","retraction":null,"screen_n_in":null,"score":{"opus":0.01211211701704567,"gpt":0.2491729031369084,"spread":0.2370607861198627,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001930655,0.0002831664,0.0002927515,0.00005747175,0.0001758989,0.0000375841,0.0002890967,0.0003656214,0.00006060629],"category_scores_gemma":[0.00003380744,0.0002857762,0.0002411292,0.0001410098,0.00006669324,0.00001067671,0.00007416631,0.0001310381,0.000007007871],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001066281,"about_ca_system_score_gemma":0.0002399412,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007413289,"about_ca_topic_score_gemma":0.00001201997,"domain_scores_codex":[0.9984039,0.0000386766,0.0004315377,0.000527759,0.0002071478,0.0003909751],"domain_scores_gemma":[0.9990672,0.00002264045,0.0002730511,0.0004082567,0.0001340828,0.00009472812],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000290652,0.00003668303,0.0000869294,0.00009145388,0.0001697187,0.000002881417,0.00007760977,0.00002163105,0.9958537,0.00001387397,0.00140994,0.001944988],"study_design_scores_gemma":[0.0009444041,0.0002158557,0.00009449713,0.0000648627,0.0001007674,0.00001389891,0.0000403804,0.0002056565,0.9946727,0.00005637256,0.00324474,0.0003458526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971426,0.00004749838,0.001261002,0.00008793033,0.00009373787,0.0004814373,0.0001769467,0.00002516927,0.0006836755],"genre_scores_gemma":[0.9956049,0.0000460946,0.001373352,0.0001404643,0.0004372917,0.00006550002,0.0003919885,0.00003641153,0.001904001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0018348,"threshold_uncertainty_score":0.9999595,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2893765519","doi":"10.1038/s41375-018-0265-z","title":"Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":209,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"National Institutes of Health; Vanderbilt University; York University; Eberhard Karls Universität Tübingen; McMaster University; NYU Langone Medical Center; Kaiser Permanente","keywords":"Medicine; Refractory (planetary science); Minimal residual disease; Salvage therapy; Hematopoietic stem cell transplantation; Internal medicine; Transplantation; Lymphoblastic Leukemia; Leukemia; Chemotherapy; Pediatrics; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.008638915841045569,"gpt":0.2502595223216064,"spread":0.2416206064805608,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003354779,0.0006247949,0.0008315042,0.0009417157,0.0001866393,0.00006160654,0.0005334077,0.0005109253,0.0004101118],"category_scores_gemma":[0.0004439472,0.0004991594,0.0001371805,0.001793058,0.0005100268,0.000400026,0.0002928819,0.0009351447,0.001590535],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01866002,"about_ca_system_score_gemma":0.00747789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004241764,"about_ca_topic_score_gemma":0.0001694352,"domain_scores_codex":[0.9951159,0.0001323348,0.0008123514,0.001078398,0.001470884,0.001390168],"domain_scores_gemma":[0.9970337,0.0003903526,0.0002673417,0.00114523,0.00057083,0.0005925641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01144023,0.0009078811,0.9405174,0.0005372877,0.0004748441,0.001917524,0.001800312,0.000147459,0.001891224,0.0003166382,0.03093801,0.009111197],"study_design_scores_gemma":[0.04077924,0.005008291,0.9426511,0.0003794248,0.0005885451,0.0001715952,0.00009621889,0.004569176,0.00102689,0.0001405993,0.003631235,0.0009577061],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854369,0.00008454445,0.0004056576,0.0001102078,0.0003986958,0.001005581,0.0000339324,0.0002292819,0.01229526],"genre_scores_gemma":[0.993571,0.00009825661,0.001385215,0.0009124881,0.001019104,0.00007631377,0.0001434734,0.0001747525,0.002619406],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02933901,"threshold_uncertainty_score":0.999746,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2317478958","doi":"10.1038/sj.leu.2401657","title":"Serine/threonine phosphorylation in cytokine signal transduction","year":2000,"lang":"en","type":"review","venue":"Leukemia","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":207,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute; National Institute on Aging; National Institutes of Health; University of British Columbia","keywords":"Phosphorylation; Receptor tyrosine kinase; Tyrosine phosphorylation; Biology; Signal transduction; Cell biology; MAP2K7; AKT2; Tyrosine kinase; JAK-STAT signaling pathway; Cancer research; AKT1; Protein kinase A; Cyclin-dependent kinase 2; Protein kinase B","retraction":null,"screen_n_in":null,"score":{"opus":0.03958424212897341,"gpt":0.3204393593555315,"spread":0.2808551172265581,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001676788,0.0004656196,0.001524813,0.0005027654,0.00005968818,0.00002884346,0.0001118826,0.0004227981,0.006223693],"category_scores_gemma":[0.00001978061,0.0004018887,0.0005825079,0.0007166219,0.00004046275,0.0001263296,0.00001447295,0.001058414,0.0003766278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001384644,"about_ca_system_score_gemma":0.0008005904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002416655,"about_ca_topic_score_gemma":0.00004362604,"domain_scores_codex":[0.9978725,0.0000690945,0.0009200198,0.0005282181,0.0002754414,0.0003347062],"domain_scores_gemma":[0.9991593,0.00006727799,0.000212583,0.0003786589,0.00005307159,0.0001291224],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008474477,0.0001012243,0.000006491824,0.003804492,0.00008784986,0.00009915204,0.00006257547,0.00007632535,0.0001321791,0.00003389636,0.001017512,0.9944935],"study_design_scores_gemma":[0.0007624503,0.0002078566,0.00003831021,0.012794,0.0006478122,0.0006094524,0.000008193669,0.0001770415,0.0002629065,0.0000189235,0.98414,0.000332993],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004451637,0.9913722,0.0001109805,0.00005927104,0.0003563649,0.0009382442,0.00006930496,0.0001421199,0.006506363],"genre_scores_gemma":[0.0007353141,0.9946191,0.0002188197,0.00006782301,0.0008861827,0.0001394658,0.001019103,0.00009869434,0.002215553],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9941606,"threshold_uncertainty_score":0.9998433,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1998936478","doi":"10.1038/leu.2008.221","title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Dasatinib; Medicine; Internal medicine; Chronic myelogenous leukemia; Imatinib; Neutropenia; Tolerability; Gastroenterology; Imatinib mesylate; Myeloid leukemia; Oncology; Nilotinib; Immunology; Leukemia; Adverse effect; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01500029936148646,"gpt":0.2662409921901603,"spread":0.2512406928286739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002148243,0.0004891697,0.001064996,0.0003886489,0.00008809961,0.00001063413,0.0001815888,0.0002141308,0.0002388504],"category_scores_gemma":[0.000200892,0.0003582521,0.00007489072,0.0008076431,0.0003555468,0.0001797789,0.0001013513,0.0005388439,0.00002200371],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01241015,"about_ca_system_score_gemma":0.005093864,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001535856,"about_ca_topic_score_gemma":0.001423404,"domain_scores_codex":[0.996794,0.00009828153,0.001093309,0.0007016123,0.0006306939,0.0006821089],"domain_scores_gemma":[0.998325,0.0003069254,0.0003356085,0.0006721066,0.000105112,0.0002552485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1202575,0.005019209,0.7522866,0.002865326,0.000795615,0.005308829,0.01335512,0.002912684,0.01768565,0.000141764,0.001217297,0.0781544],"study_design_scores_gemma":[0.1495878,0.003846235,0.8368438,0.001881494,0.0001140824,0.0001507294,0.00011232,0.002711413,0.003328234,0.000006775683,0.0009521703,0.0004649301],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965484,0.0004176753,0.00002640561,0.00005235849,0.00005498561,0.001672639,0.00006048664,0.00005657603,0.001110538],"genre_scores_gemma":[0.9974586,0.0003298521,0.001358789,0.0001135329,0.0000663993,0.00008163855,0.0001647376,0.00007410962,0.0003522932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08455728,"threshold_uncertainty_score":0.9998869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205825534","doi":"10.1038/s41375-021-01485-x","title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"AstraZeneca","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Ibrutinib; Internal medicine; Bruton's tyrosine kinase; Oncology; Clinical endpoint; Leukemia; Clinical trial; Chemotherapy; Tyrosine kinase; Cyclophosphamide","retraction":null,"screen_n_in":null,"score":{"opus":0.04697134715739797,"gpt":0.3070144821862215,"spread":0.2600431350288235,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009653304,0.001593898,0.003763272,0.0009630586,0.0003393888,0.0001285834,0.001409104,0.001136861,0.0005323],"category_scores_gemma":[0.0004745331,0.001073239,0.000394516,0.002542927,0.0008602855,0.0002091031,0.001270307,0.00452124,0.00004376651],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.7647498,"about_ca_system_score_gemma":0.2727936,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0567187,"about_ca_topic_score_gemma":0.02227917,"domain_scores_codex":[0.9899402,0.0008650591,0.00198363,0.002295367,0.002725129,0.00219056],"domain_scores_gemma":[0.9940449,0.001632114,0.0008184673,0.002999203,0.0001856293,0.0003197145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.695471,0.001010753,0.03638951,0.0115793,0.01056921,0.04425064,0.04320714,0.08589248,0.0003460563,0.0001150692,0.06395216,0.007216627],"study_design_scores_gemma":[0.826987,0.01707989,0.005915364,0.003980163,0.002086134,0.001275381,0.004245053,0.08680954,0.0003050274,0.00001089734,0.04922185,0.002083711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863912,0.0008261295,0.000002062581,0.001273222,0.0007641081,0.008485844,0.00008000919,0.0001586317,0.002018821],"genre_scores_gemma":[0.9852361,0.0004349711,0.0000658186,0.003207384,0.0009027328,0.001063654,0.0003404806,0.0004083946,0.008340461],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4919561,"threshold_uncertainty_score":0.9996809,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089532685","doi":"10.1038/leu.2014.44","title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","year":2014,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; U.S. Public Health Service","keywords":"Azacitidine; Myeloid; Gene silencing; Cancer research; RNA interference; Hypomethylating agent; Bcl-2 family; Biology; Gene expression; RNA; Gene; DNA methylation; Apoptosis; Programmed cell death; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01767716885988376,"gpt":0.2858078276040187,"spread":0.2681306587441349,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001556352,0.0002550837,0.0006449222,0.0004144365,0.00007279379,0.00002164007,0.0001612739,0.000220246,0.00001923932],"category_scores_gemma":[0.001980145,0.000226577,0.00007677275,0.0003911922,0.0002585352,0.0001349191,0.0001965055,0.0004418538,0.00006668291],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007862615,"about_ca_system_score_gemma":0.001003844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001032735,"about_ca_topic_score_gemma":0.00009114476,"domain_scores_codex":[0.997647,0.0003005907,0.0005335921,0.0004593301,0.0004766904,0.0005827944],"domain_scores_gemma":[0.9985052,0.0004332947,0.0001424671,0.0005306966,0.0001592814,0.0002290205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.005090335,0.0000537359,0.04327435,0.0004652252,0.00002735869,0.0008128018,0.00123582,0.00001754422,0.9345032,0.0001557801,0.0005677812,0.01379607],"study_design_scores_gemma":[0.006424412,0.001636773,0.6833847,0.001126983,0.00004531045,0.0006219596,0.0007763309,0.007492849,0.2922103,0.0002818502,0.005567662,0.0004308757],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964461,0.0004264165,0.00007290754,0.0004349021,0.00005531793,0.0007620169,0.000007719065,0.00005579336,0.001738855],"genre_scores_gemma":[0.9948885,0.0001368899,0.002677438,0.0005424097,0.0001007192,0.0000480191,0.000005841688,0.0000528721,0.00154725],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6422929,"threshold_uncertainty_score":0.9239543,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2032847865","doi":"10.1038/sj.leu.2403796","title":"Bone marrow as a home of heterogenous populations of nonhematopoietic stem cells","year":2005,"lang":"en","type":"review","venue":"Leukemia","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Heart and Stroke Foundation of Canada","keywords":"Stem cell; Haematopoiesis; Bone marrow; CD34; CXCR4; Biology; Population; Induced pluripotent stem cell; Adult stem cell; Immunology; Cell biology; Endothelial stem cell; Cancer research; Medicine; Embryonic stem cell; Genetics; In vitro; Chemokine; Inflammation; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.09553070849956367,"gpt":0.3692979615915827,"spread":0.273767253092019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004513633,0.000440912,0.003163709,0.0004863704,0.00004222382,0.00001126876,0.0003502793,0.0005430969,0.0007720508],"category_scores_gemma":[0.00004700017,0.0003559805,0.0008817222,0.0006741306,0.0001447122,0.00003872196,0.0001709066,0.000651131,0.0005905339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009327779,"about_ca_system_score_gemma":0.001776834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001854964,"about_ca_topic_score_gemma":0.00001673256,"domain_scores_codex":[0.9963096,0.0001918039,0.001504854,0.0004750598,0.001017199,0.000501416],"domain_scores_gemma":[0.9973788,0.0002254556,0.0007263084,0.001148335,0.0002093569,0.0003116911],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004598733,0.0002400748,0.00004425237,0.1277323,0.000363448,0.0003180447,0.0001985182,0.000008034182,0.0004924102,0.0002966651,0.001471565,0.8687887],"study_design_scores_gemma":[0.0009769971,0.0005388922,0.00001640507,0.03081688,0.001724005,0.001119074,0.00003555372,0.00003556381,0.001136399,0.0000412187,0.9630807,0.000478327],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002888435,0.9898738,0.00001367861,0.00001661138,0.0001503194,0.001830389,0.00006716717,0.00003517469,0.005124389],"genre_scores_gemma":[0.002281791,0.9839988,0.0006702242,0.00001751548,0.0001886582,0.00008171712,0.0000859088,0.000116867,0.01255856],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9616091,"threshold_uncertainty_score":0.9998892,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2058194048","doi":"10.1038/leu.2009.3","title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies","year":2009,"lang":"en","type":"article","venue":"Leukemia","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":196,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Center for Research Resources; National Cancer Institute; Genome Canada; National Institutes of Health; University of Nebraska Medical Center","keywords":"Biology; Cancer research; Gene; Genetics; Tumor suppressor gene; DNA methylation; Gene expression; Carcinogenesis","retraction":null,"screen_n_in":null,"score":{"opus":0.01996315013138833,"gpt":0.249111750891657,"spread":0.2291486007602687,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000899886,0.0002307402,0.0002625361,0.0001297617,0.0002189038,0.00005656957,0.000116705,0.0001097769,0.0002716223],"category_scores_gemma":[0.00003679673,0.0002055158,0.00009471154,0.0001616984,0.00009218903,0.0002860233,0.00004726475,0.0003090293,0.0001248843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002841495,"about_ca_system_score_gemma":0.000129391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000239045,"about_ca_topic_score_gemma":0.00004080376,"domain_scores_codex":[0.9988416,0.00008199992,0.0003235233,0.0003702291,0.00005059949,0.0003319824],"domain_scores_gemma":[0.9995663,0.00004477092,0.000136931,0.0001718858,0.00005459278,0.00002559205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002518281,0.00009628434,0.003097207,0.00001448695,0.00004010106,0.000008435722,0.00009101091,0.00008020314,0.9893595,0.0005164496,0.006253199,0.0001912875],"study_design_scores_gemma":[0.003458196,0.000296848,0.386414,0.00006330923,0.00008094723,0.000783522,0.0002755941,0.000356919,0.5956918,0.0002582167,0.01184028,0.0004803703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920264,0.002893314,0.0003326058,0.0003990769,0.00272612,0.0002340245,0.00001746448,0.00007022679,0.001300765],"genre_scores_gemma":[0.9929782,0.00003448005,0.0002148691,0.0009903358,0.0000755173,0.00001801943,0.0002393601,0.00001000406,0.005439281],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3936677,"threshold_uncertainty_score":0.8380691,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1989803279","doi":"10.1038/sj.leu.2405087","title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","year":2008,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Dexamethasone; Multiple myeloma; Renal function; Internal medicine; Creatinine; Adverse effect; Proteasome inhibitor; Urology; Phases of clinical research; Gastroenterology; Toxicity; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.01932933302448729,"gpt":0.2877653199784997,"spread":0.2684359869540124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001359922,0.0001246504,0.0002515868,0.00005179636,0.00007803566,0.000005059023,0.00007460754,0.00003502475,0.00002235538],"category_scores_gemma":[0.0001393565,0.0000676312,0.00002375814,0.0001663309,0.0001084193,0.0000452543,0.00004793511,0.0001709013,0.00000635582],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001868733,"about_ca_system_score_gemma":0.0001814361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001674154,"about_ca_topic_score_gemma":0.0001276647,"domain_scores_codex":[0.998762,0.00008005784,0.0002881844,0.0002530405,0.0004048602,0.0002118843],"domain_scores_gemma":[0.9991538,0.0002288202,0.00007725385,0.0003597856,0.00005545076,0.0001248713],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04159952,0.002716901,0.9445051,0.000005904545,0.0002057699,0.0002542044,0.002306396,0.000006727345,0.00004953379,8.228761e-7,0.0002699555,0.008079195],"study_design_scores_gemma":[0.1282969,0.003255575,0.8678113,0.00007466373,0.00004245689,0.00000360837,0.0001099084,0.00009074368,0.0001447608,0.000001899017,0.000114366,0.00005380502],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979819,0.0000520283,0.000002635235,0.00008238896,0.00001106374,0.001378072,0.0001395147,0.00001217451,0.0003402282],"genre_scores_gemma":[0.9994405,0.00002961395,0.0001296874,0.00003927303,0.00003109861,0.00001810744,0.0002037999,0.00001162371,0.00009628494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08669738,"threshold_uncertainty_score":0.2757921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115093629","doi":"10.1038/leu.2012.257","title":"IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas","year":2012,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut Bergonié; Institut National Du Cancer; Ligue Contre le Cancer","keywords":"IGHV@; Biology; Waldenstrom macroglobulinemia; Lymphoplasmacytic Lymphoma; Macroglobulinemia; Immunoglobulin heavy chain; Lymphoma; Gene rearrangement; Antibody; Cancer research; Gene; Immunology; Genetics; Chronic lymphocytic leukemia; Leukemia; Multiple myeloma","retraction":null,"screen_n_in":null,"score":{"opus":0.01437837057025398,"gpt":0.2692461794673759,"spread":0.254867808897122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006275385,0.0004963921,0.0005635952,0.0001946659,0.0004448862,0.0002038654,0.0002477446,0.0003164676,0.0001658449],"category_scores_gemma":[0.0001827761,0.000356717,0.0001261753,0.000379658,0.0007953342,0.0003791177,0.0003433431,0.0002821086,0.0001520841],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01114019,"about_ca_system_score_gemma":0.003945166,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001970027,"about_ca_topic_score_gemma":0.0002503948,"domain_scores_codex":[0.9967902,0.0001243286,0.0004820099,0.0005887129,0.000874621,0.001140173],"domain_scores_gemma":[0.9979761,0.0004345243,0.0001688878,0.0007056767,0.0001621225,0.0005526837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01245232,0.001433734,0.1700543,0.006356638,0.004596476,0.009304776,0.02714558,0.0007062786,0.04844674,0.03096636,0.08025614,0.6082806],"study_design_scores_gemma":[0.1300435,0.001294248,0.486021,0.0009744909,0.002335913,0.1606821,0.003568547,0.06275271,0.08982326,0.002643788,0.05700423,0.002856207],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815107,0.01283298,0.0001866053,0.0007374666,0.0003910547,0.0007708325,0.00003441887,0.0001431532,0.003392795],"genre_scores_gemma":[0.9895148,0.001132012,0.001280061,0.0007837529,0.0008845385,0.00009772761,0.00008340062,0.00008506997,0.006138614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6054244,"threshold_uncertainty_score":0.9998885,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2398639705","doi":"10.1038/leu.2011.256","title":"Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":172,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Takeda Oncology; Koninklijke Nederlandse Akademie van Wetenschappen","keywords":"Bortezomib; Proteasome; Protein subunit; Proteasome inhibitor; Mutant; Cancer research; Multiple myeloma; Biology; Cell biology; Biochemistry; Immunology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.04165090137066048,"gpt":0.2578321363683535,"spread":0.216181234997693,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006443734,0.0002685172,0.0002719437,0.00007429234,0.0002118969,0.00002879019,0.0007638535,0.0002309126,0.00004085323],"category_scores_gemma":[0.0001840094,0.0001844443,0.0002290306,0.000368175,0.0001285423,0.000009727703,0.0002195468,0.0002174621,0.00001013593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003014429,"about_ca_system_score_gemma":0.0006399925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002910901,"about_ca_topic_score_gemma":0.0006727455,"domain_scores_codex":[0.99819,0.0001322649,0.0004610204,0.0004853464,0.0002153224,0.0005160178],"domain_scores_gemma":[0.9986114,0.00006026681,0.0002379447,0.000881481,0.0001059825,0.0001029087],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003913014,0.00003003983,0.001717745,0.0001163522,0.00005505239,0.000003091768,0.00206029,0.00002374707,0.9929307,0.000418828,0.001510068,0.0007428632],"study_design_scores_gemma":[0.0007308595,0.0001649913,0.005578025,0.0001636372,0.00003072338,0.000004172337,0.0004698197,0.00007039838,0.9807425,0.0006075246,0.0111614,0.0002759581],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945463,0.0002451788,0.0004221235,0.0002648429,0.0001918331,0.001832964,0.0001684288,0.00001704315,0.002311311],"genre_scores_gemma":[0.9954875,0.00003764773,0.00176026,0.0007665761,0.00009728646,0.0003916006,0.00001357476,0.00005092918,0.00139469],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01218813,"threshold_uncertainty_score":0.7521421,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060193341","doi":"10.1038/sj.leu.2403673","title":"High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative","year":2005,"lang":"en","type":"article","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":171,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Trisomy; Concordance; Context (archaeology); Internal medicine; Oncology; Lymphoblastic Leukemia; Medicine; Chromosome; Cancer; Leukemia; Biology; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01084619977607484,"gpt":0.274874083981728,"spread":0.2640278842056532,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001272278,0.001209308,0.002556153,0.000462689,0.0008270158,0.0001869901,0.0006275857,0.000825043,0.0001085355],"category_scores_gemma":[0.0006756648,0.0008178379,0.0001419937,0.001255672,0.001491199,0.0006599043,0.0006959186,0.002261658,0.00001373771],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01830267,"about_ca_system_score_gemma":0.004105499,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0113329,"about_ca_topic_score_gemma":0.01080185,"domain_scores_codex":[0.9925715,0.001004761,0.001290285,0.001895924,0.001516204,0.00172137],"domain_scores_gemma":[0.9938946,0.002989607,0.001431565,0.0006704807,0.0004598705,0.0005538259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009422596,0.0005550795,0.9477859,0.00007388105,0.006197052,0.0001454073,0.003463048,0.000271558,0.000104227,0.0000698664,0.009586681,0.02232473],"study_design_scores_gemma":[0.0656907,0.01291916,0.9115585,0.0003581293,0.004489681,0.0005840035,0.001530567,0.001015207,0.0002555334,0.0001907079,0.000269516,0.001138281],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831786,0.008227015,0.0003293205,0.001230535,0.0001115031,0.004878652,0.001600053,0.0002067937,0.0002375443],"genre_scores_gemma":[0.981158,0.010215,0.003611891,0.001174664,0.0008552209,0.001961123,0.000580695,0.0002030784,0.0002403032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0562681,"threshold_uncertainty_score":0.9994273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2087111337","doi":"10.1038/sj.leu.2401980","title":"Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995)","year":2000,"lang":"en","type":"review","venue":"Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre hospitalier de l'Université Laval; Centre Hospitalier Universitaire Sainte-Justine; McMaster University","funders":"Medical Center, University of Rochester; National Institutes of Health; McMaster University; National Cancer Institute; Dana-Farber Cancer Institute","keywords":"Medicine; Vincristine; Internal medicine; Asparaginase; Acute lymphocytic leukemia; Methotrexate; Cancer; Chemotherapy; Clinical trial; Pediatrics; Oncology; Leukemia; Surgery; Cyclophosphamide; Lymphoblastic Leukemia","retraction":null,"screen_n_in":null,"score":{"opus":0.03803873145194273,"gpt":0.3568628924867702,"spread":0.3188241610348275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006516253,0.001943682,0.006244837,0.0009370314,0.0002684168,0.0001270153,0.001481456,0.001635644,0.0002318913],"category_scores_gemma":[0.0007541648,0.001398127,0.001309715,0.001776591,0.001256967,0.0003647073,0.0003239925,0.001475425,0.0001907348],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01690611,"about_ca_system_score_gemma":0.05467226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002576309,"about_ca_topic_score_gemma":0.0004088359,"domain_scores_codex":[0.9905188,0.0002595913,0.003064821,0.002320394,0.001847885,0.001988491],"domain_scores_gemma":[0.9925804,0.001240352,0.001844226,0.002665155,0.0006839262,0.0009860044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009871399,0.0004080865,0.0001457049,0.03755565,0.009045722,0.00107831,0.0002272236,0.0004673264,0.00001949132,0.0001861134,0.0749902,0.8660048],"study_design_scores_gemma":[0.03242785,0.002084082,0.000221389,0.05005363,0.009194632,0.001293793,0.000009503324,0.0003154017,0.000087131,0.00002195467,0.9028364,0.001454197],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001234017,0.8135005,0.000920351,0.000196165,0.0006816383,0.1658188,0.01007773,0.0006669546,0.006903869],"genre_scores_gemma":[0.00009546552,0.9037201,0.003523831,0.0003719035,0.00161196,0.07691276,0.003687029,0.0006373845,0.009439567],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8645506,"threshold_uncertainty_score":0.9996604,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075960226","doi":"10.1038/sj.leu.2402255","title":"AC133 expression in human stem cells","year":2001,"lang":"nl","type":"review","venue":"Leukemia","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Haematopoiesis; Biology; Stem cell; Cell biology; Context (archaeology); Progenitor cell; Immunology; Hematopoietic stem cell; Cell type; Cell; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.05067106177671841,"gpt":0.3167773734396874,"spread":0.2661063116629689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004212995,0.0008666756,0.002880157,0.0004798479,0.0001642956,0.00002830129,0.0004018458,0.001625842,0.008700427],"category_scores_gemma":[0.00002552631,0.0007117605,0.0006377344,0.0007767338,0.0001457333,0.00008606799,0.0002055212,0.002137473,0.01372492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002093642,"about_ca_system_score_gemma":0.0009698369,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001149674,"about_ca_topic_score_gemma":0.00001537515,"domain_scores_codex":[0.9955264,0.0006657431,0.001435426,0.001102423,0.0004078625,0.000862192],"domain_scores_gemma":[0.9974996,0.0002784906,0.0006281298,0.00115296,0.0000815375,0.000359291],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003379627,0.0005999268,0.0003830375,0.04895139,0.0002520633,0.003016839,0.0005753831,0.00006274143,0.05244543,0.0001851391,0.2059184,0.6872717],"study_design_scores_gemma":[0.002003842,0.0004204977,0.0001292152,0.02862137,0.0003663579,0.0001182447,0.0001427291,0.00001950477,0.001246342,0.00002471192,0.9663006,0.0006065842],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006209067,0.9512093,0.00005427011,0.00003593138,0.003815816,0.001634587,0.00003878953,0.0001341159,0.03686811],"genre_scores_gemma":[0.0005252382,0.8798144,0.00007484803,0.0006512864,0.002197819,0.0001137594,0.0003011757,0.0001239337,0.1161975],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7603822,"threshold_uncertainty_score":0.9996703,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2077682572","doi":"10.1038/leu.2013.172","title":"Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","year":2013,"lang":"en","type":"article","venue":"Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute on Aging","keywords":"Nuclear export signal; Biology; Monoclonal gammopathy of undetermined significance; Cell cycle; Molecular biology; Cancer research; RNA interference; Nuclear protein; Gene expression; Apoptosis; Cell nucleus; Gene; RNA; Monoclonal antibody; Transcription factor; Monoclonal; Genetics; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.0668419449408269,"gpt":0.3649538393636502,"spread":0.2981118944228233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003429123,0.0003391258,0.0005614184,0.0002349659,0.0003449832,0.0001020014,0.0002130547,0.0001710471,0.0004372068],"category_scores_gemma":[0.003012922,0.0002352584,0.0001520083,0.0005461556,0.0004446261,0.0003310932,0.0002455437,0.0006186138,0.0007934092],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001660834,"about_ca_system_score_gemma":0.0004337135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001594076,"about_ca_topic_score_gemma":0.00005875726,"domain_scores_codex":[0.9971579,0.0002330607,0.0005057892,0.0005673943,0.0006633186,0.0008725204],"domain_scores_gemma":[0.9979506,0.000672543,0.0000841613,0.0004946949,0.0004559921,0.0003419736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001551702,0.001026996,0.7187224,0.0005660588,0.001963811,0.004255658,0.01163367,0.0001035122,0.2474685,0.0001479147,0.0108721,0.001687667],"study_design_scores_gemma":[0.0076536,0.0006710486,0.9355469,0.0004355982,0.0001881541,0.0003502584,0.007115941,0.007646446,0.03635908,0.001310424,0.002176878,0.00054569],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956933,0.0007506338,0.00003730912,0.0009142809,0.0001883287,0.001435415,0.000013557,0.0001076331,0.0008594953],"genre_scores_gemma":[0.9957173,0.00007645426,0.002383435,0.0006141145,0.0002769929,0.0001926676,0.00004148271,0.0000743171,0.0006232667],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2168245,"threshold_uncertainty_score":0.9999846,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2082267009","doi":"10.1038/sj.leu.2402876","title":"Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":164,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Arsenic; Buthionine sulfoximine; Glutathione; Cell culture; Biology; Apoptosis; Annexin; Cancer research; Chemistry; Biochemistry; Genetics; Enzyme; Retinoic acid","retraction":null,"screen_n_in":null,"score":{"opus":0.0071849851130217,"gpt":0.2300234653657576,"spread":0.2228384802527359,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004336415,0.0002736811,0.0002614028,0.0001063144,0.00008508001,0.00004252978,0.0002700049,0.0002674975,0.00004341295],"category_scores_gemma":[0.0004419995,0.0002743192,0.0001198091,0.0003553258,0.00005747729,0.000008700517,0.00006419916,0.0002002985,0.00008590161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002436,"about_ca_system_score_gemma":0.0004664472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002823447,"about_ca_topic_score_gemma":0.0003026628,"domain_scores_codex":[0.9980899,0.0001654142,0.0004327749,0.0006169956,0.0002362823,0.000458615],"domain_scores_gemma":[0.9990751,0.00004290861,0.0001157781,0.000538483,0.0000869724,0.000140807],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002703573,0.00005585083,0.001569926,0.00009780804,0.00001350948,0.0000379401,0.00009038601,0.0004733834,0.9931403,0.000534456,0.003447425,0.0002686055],"study_design_scores_gemma":[0.001082538,0.0001150916,0.00128078,0.00005767838,0.00001486898,0.00001061407,0.0001431688,0.00001758203,0.8011543,0.0004800879,0.1952656,0.0003776848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851948,0.00282309,0.001676096,0.0001002278,0.0002071473,0.0002684538,0.000009847752,0.00002935817,0.009691002],"genre_scores_gemma":[0.9847845,0.0005384802,0.003842459,0.0005373694,0.0001425115,0.00005728448,0.00004747257,0.00004635459,0.01000356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.191986,"threshold_uncertainty_score":0.9999709,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2084403455","doi":"10.1038/sj.leu.2403222","title":"NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration","year":2003,"lang":"en","type":"article","venue":"Leukemia","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":160,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Stem Cell Network","keywords":"Nod; Progenitor cell; Stem cell; Regeneration (biology); Biology; Immunology; Cell biology; Cancer research; In vivo; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02018253471301899,"gpt":0.2737957799411491,"spread":0.2536132452281301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002117956,0.000335582,0.0002747004,0.0001112238,0.0003940146,0.0001146791,0.0002129817,0.0002440344,0.00002643917],"category_scores_gemma":[0.00002158426,0.0003462944,0.00006123835,0.0001187409,0.0001789963,0.00001370281,0.00008972664,0.000201613,0.0000075034],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001229778,"about_ca_system_score_gemma":0.0001415687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003284611,"about_ca_topic_score_gemma":0.0001135397,"domain_scores_codex":[0.9981143,0.0002011049,0.0003178164,0.0007076091,0.0002301263,0.0004290811],"domain_scores_gemma":[0.9989758,0.00001573839,0.00008530218,0.0004527491,0.0001765224,0.0002938735],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001732769,0.00006299703,0.0004062628,0.00005085782,0.00004447852,0.000005312471,0.0002775857,0.0001011994,0.9980732,0.0001445623,0.0003798304,0.0002804857],"study_design_scores_gemma":[0.001972469,0.001625997,0.0007023729,0.00002189562,0.00001963551,0.000007389831,0.0001344249,0.00003925127,0.9909248,0.0000221464,0.004126762,0.000402832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975806,0.00060781,0.0001597285,0.00002311964,0.00005743596,0.0009973557,0.0001130437,0.00004173218,0.0004191904],"genre_scores_gemma":[0.997706,0.00002775655,0.0003950932,0.0001441472,0.0001298167,0.0001117019,0.0001640759,0.0000469976,0.001274411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007148327,"threshold_uncertainty_score":0.9998989,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}